FSSNX
Price
$27.92
Change
-$1.28 (-4.38%)
Updated
Dec 18 closing price
JDSCX
Price
$33.44
Change
-$1.41 (-4.05%)
Updated
Dec 18 closing price
Ad is loading...

FSSNX vs JDSCX

Header iconFSSNX vs JDSCX Comparison
Open Charts FSSNX vs JDSCXBanner chart's image
Fidelity Small Cap Index
Price$27.92
Change-$1.28 (-4.38%)
VolumeN/A
CapitalizationN/A
JPMorgan Small Cap Blend I
Price$33.44
Change-$1.41 (-4.05%)
VolumeN/A
CapitalizationN/A
FSSNX vs JDSCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FSSNX vs. JDSCX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSSNX is a Hold and JDSCX is a Hold.

FUNDAMENTALS
Fundamentals
FSSNX has more cash in the bank: 29.5B vs. JDSCX (1.66B). FSSNX pays higher dividends than JDSCX: FSSNX (1.36) vs JDSCX (0.33). FSSNX was incepted earlier than JDSCX: FSSNX (13 years) vs JDSCX (26 years). JDSCX is a more actively managed with annual turnover of: 37.00 vs. FSSNX (9.00). FSSNX has a lower initial minimum investment than JDSCX: FSSNX (0) vs JDSCX (1000000). JDSCX annual gain was more profitable for investors over the last year : 17.40 vs. FSSNX (12.05). JDSCX (40.79) and FSSNX (39.57) have equivalent 5 years return.
FSSNXJDSCXFSSNX / JDSCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years26 years-
Gain YTD11.65115.28376%
Front LoadN/AN/A-
Min. Initial Investment01000000-
Min. Initial Investment IRAN/AN/A-
Net Assets29.5B1.66B1,777%
Annual Yield % from dividends1.360.33416%
Returns for 1 year12.0517.4069%
Returns for 3 years7.7110.0577%
Returns for 5 years39.5740.7997%
Returns for 10 years82.0736.54225%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHUN4.380.05
+1.15%
Phunware
SPGI500.51-2.35
-0.47%
S&P Global
GRND16.80-0.12
-0.71%
Grindr
BERY66.66-0.95
-1.41%
Berry Global Group
YMAB9.53-0.39
-3.93%
Y-mAbs Therapeutics